Is NewAmsterdam Pharma Stock a Good Investment?
NewAmsterdam Pharma Investment Advice | NAMSW |
- Examine NewAmsterdam Pharma's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research NewAmsterdam Pharma's leadership team and their track record. Good management can help NewAmsterdam Pharma navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact NewAmsterdam Pharma's business and its evolving consumer preferences.
- Compare NewAmsterdam Pharma's performance and market position to its competitors. Analyze how NewAmsterdam Pharma is positioned in terms of product offerings, innovation, and market share.
- Check if NewAmsterdam Pharma pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about NewAmsterdam Pharma's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in NewAmsterdam Pharma stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if NewAmsterdam Pharma is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine NewAmsterdam Pharma Stock
Researching NewAmsterdam Pharma's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company had not issued any dividends in recent years. NewAmsterdam Pharma had 1:1 split on the 23rd of November 2022.
To determine if NewAmsterdam Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NewAmsterdam Pharma's research are outlined below:
| NewAmsterdam Pharma is way too risky over 90 days horizon | |
| NewAmsterdam Pharma appears to be risky and price may revert if volatility continues | |
| NewAmsterdam Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 12.76 M. Net Loss for the year was (176.94 M) with profit before overhead, payroll, taxes, and interest of 33.59 M. | |
| NewAmsterdam Pharma generates negative cash flow from operations | |
| NewAmsterdam Pharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update |
NewAmsterdam Pharma's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.46) | (0.48) | |
| Return On Capital Employed | (0.23) | (0.22) | |
| Return On Assets | (0.46) | (0.48) | |
| Return On Equity | (0.71) | (0.67) |
Determining NewAmsterdam Pharma's profitability involves analyzing its financial statements and using various financial metrics to determine if NewAmsterdam Pharma is a good buy. For example, gross profit margin measures NewAmsterdam Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NewAmsterdam Pharma's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in NewAmsterdam Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of NewAmsterdam Pharma. Check NewAmsterdam Pharma's Beneish M Score to see the likelihood of NewAmsterdam Pharma's management manipulating its earnings.
Evaluate NewAmsterdam Pharma's management efficiency
The company has return on total asset (ROA) of (0.2927) % which means that it has lost $0.2927 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4737) %, meaning that it generated substantial loss on money invested by shareholders. NewAmsterdam Pharma's management efficiency ratios could be used to measure how well NewAmsterdam Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.48 in 2025. Return On Capital Employed is likely to climb to -0.22 in 2025. At this time, NewAmsterdam Pharma's Non Currrent Assets Other are fairly stable compared to the past year. Other Current Assets is likely to climb to about 6 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 334.3 K in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.16 | 3.00 | |
| Tangible Book Value Per Share | 3.16 | 5.46 | |
| Enterprise Value Over EBITDA | (2.94) | (2.79) | |
| Price Book Value Ratio | 2.86 | 3.01 | |
| Enterprise Value Multiple | (2.94) | (2.79) | |
| Price Fair Value | 2.86 | 3.01 | |
| Enterprise Value | -208.5 M | -218.9 M |
Leadership at NewAmsterdam Pharma emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta (0.06) |
Basic technical analysis of NewAmsterdam Stock
As of the 26th of February, NewAmsterdam Pharma secures the Downside Deviation of 8.83, risk adjusted performance of 0.0107, and Mean Deviation of 5.31. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NewAmsterdam Pharma, as well as the relationship between them. Please verify NewAmsterdam Pharma jensen alpha and semi variance to decide if NewAmsterdam Pharma is priced some-what accurately, providing market reflects its recent price of 8.88 per share. Given that NewAmsterdam Pharma has jensen alpha of (0.01), we recommend you to check NewAmsterdam Pharma's last-minute market performance to make sure the company can sustain itself at a future point.NewAmsterdam Pharma's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewAmsterdam Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewAmsterdam Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NewAmsterdam Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Smither John W over two months ago Acquisition by Smither John W of 10000 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | ||
Louise Kooij over three months ago Disposition of 430015 shares by Louise Kooij of NewAmsterdam Pharma at 10.0 subject to Rule 16b-3 | ||
Lewis William over three months ago Insider Trading | ||
Davidson Michael H. over six months ago Acquisition by Davidson Michael H. of 10399 shares of NewAmsterdam Pharma at 11.17 subject to Rule 16b-3 | ||
Louise Kooij over six months ago Discretionary transaction by Louise Kooij of 213073 shares of NewAmsterdam Pharma subject to Rule 16b-3 |
Understand NewAmsterdam Pharma's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing NewAmsterdam Pharma's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0107 | |||
| Market Risk Adjusted Performance | 0.0064 | |||
| Mean Deviation | 5.31 | |||
| Semi Deviation | 6.91 | |||
| Downside Deviation | 8.83 | |||
| Coefficient Of Variation | 57732.0 | |||
| Standard Deviation | 12.77 | |||
| Variance | 163.11 | |||
| Information Ratio | 0.0015 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | 0.1243 | |||
| Sortino Ratio | 0.0021 | |||
| Treynor Ratio | (0) | |||
| Maximum Drawdown | 105.42 | |||
| Value At Risk | (13.89) | |||
| Potential Upside | 11.0 | |||
| Downside Variance | 77.94 | |||
| Semi Variance | 47.8 | |||
| Expected Short fall | (8.37) | |||
| Skewness | 4.96 | |||
| Kurtosis | 35.43 |
| Risk Adjusted Performance | 0.0107 | |||
| Market Risk Adjusted Performance | 0.0064 | |||
| Mean Deviation | 5.31 | |||
| Semi Deviation | 6.91 | |||
| Downside Deviation | 8.83 | |||
| Coefficient Of Variation | 57732.0 | |||
| Standard Deviation | 12.77 | |||
| Variance | 163.11 | |||
| Information Ratio | 0.0015 | |||
| Jensen Alpha | (0.01) | |||
| Total Risk Alpha | 0.1243 | |||
| Sortino Ratio | 0.0021 | |||
| Treynor Ratio | (0) | |||
| Maximum Drawdown | 105.42 | |||
| Value At Risk | (13.89) | |||
| Potential Upside | 11.0 | |||
| Downside Variance | 77.94 | |||
| Semi Variance | 47.8 | |||
| Expected Short fall | (8.37) | |||
| Skewness | 4.96 | |||
| Kurtosis | 35.43 |
Consider NewAmsterdam Pharma's intraday indicators
NewAmsterdam Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of NewAmsterdam Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
NewAmsterdam Pharma Corporate Filings
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 20th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 7th of January 2025 Other Reports | ViewVerify |
NewAmsterdam Stock media impact
Far too much social signal, news, headlines, and media speculation about NewAmsterdam Pharma that are available to investors today. That information is available publicly through NewAmsterdam media outlets and privately through word of mouth or via NewAmsterdam internal channels. However, regardless of the origin, that massive amount of NewAmsterdam data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NewAmsterdam Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NewAmsterdam Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NewAmsterdam Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NewAmsterdam Pharma alpha.
NewAmsterdam Pharma Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards NewAmsterdam Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NewAmsterdam Pharma Corporate Management
| Louise Kooij | Treasurer, CFO | Profile | |
| Jim Jacobson | Chief Secretary | Profile | |
| Annie Neild | VP Affairs | Profile | |
| FESC MD | Chief Founder | Profile | |
| Marc MD | Chief Officer | Profile | |
| MSc MBA | Chief Officer | Profile | |
| Lina Gugucheva | Chief Officer | Profile |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.